How to buy Abbott Laboratories shares | ABT historical share price and analysis

How to buy Abbott Laboratories shares

Own Abbott Laboratories shares in just a few minutes.

Updated

Fact checked

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Abbott Laboratories is a medical devices business with stocks listed in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.

How to buy shares in Abbott Laboratories

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Abbott Laboratories. Find the share by name or ticker symbol: ABT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Abbott Laboratories reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Abbott Laboratories, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Abbott Laboratories. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

Abbott Laboratories share price

Use our graph to track the performance of ABT stocks over time.

Abbott Laboratories shares at a glance

Information last updated 2021-03-03.
52-week rangeUS$60.667 - US$128.54
50-day moving average US$119.73
200-day moving average US$110.5696
Target priceUS$134.88
PE ratio 48.9533
Dividend yield US$1.53 (1.25%)
Earnings per share (TTM) US$2.503

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
USD 0
USD 10 per month if there’s been no login for 12 months
0.50%
Forex, CFDs, US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
CMC Markets Stockbroking
USD 0
No
0.60%
ASX shares, Global shares, Forex, CFDs, Options trading, mFunds, ETFs, Warrants
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
IG Share Trading
Finder Award
IG Share Trading
USD 0
AUD 50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares, Forex, CFDs, Margin trading
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Note: $10,000 deposit required to open account.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
USD 9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading
High quality, low-cost brokerage on global share trading.
Access up to 19,000 global stocks on 36 of the world’s major stock exchanges and enjoy some of the most competitive FX rates on the the market when you trade with Saxo Capital Markets.
loading

Compare up to 4 providers

Is it a good time to buy Abbott Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Abbott Laboratories under- or over-valued?

Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abbott Laboratories's P/E ratio

Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, Abbott Laboratories shares trade at around 49x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Abbott Laboratories's PEG ratio

Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5355. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Abbott Laboratories's EBITDA

Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$8.9 billion (£6.4 billion).

The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure a its profitability.

Abbott Laboratories financials

Revenue TTM US$34.6 billion
Operating margin TTM 16.05%
Gross profit TTM US$19.6 billion
Return on assets TTM 4.94%
Return on equity TTM 13.91%
Profit margin 12.99%
Book value 18.509
Market capitalisation US$217.1 billion

TTM: trailing 12 months

Shorting Abbott Laboratories shares

There are currently 10.5 million Abbott Laboratories shares held short by investors – that's known as Abbott Laboratories's "short interest". This figure is 17.9% up from 8.9 million last month.

There are a few different ways that this level of interest in shorting Abbott Laboratories shares can be evaluated.

Abbott Laboratories's "short interest ratio" (SIR)

Abbott Laboratories's "short interest ratio" (SIR) is the quantity of Abbott Laboratories shares currently shorted divided by the average quantity of Abbott Laboratories shares traded daily (recently around 5.6 million). Abbott Laboratories's SIR currently stands at 1.87. In other words for every 100,000 Abbott Laboratories shares traded daily on the market, roughly 1870 shares are currently held short.

However Abbott Laboratories's short interest can also be evaluated against the total number of Abbott Laboratories shares, or, against the total number of tradable Abbott Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abbott Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Abbott Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0061% of the tradable shares (for every 100,000 tradable Abbott Laboratories shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abbott Laboratories.

Find out more about how you can short Abbott Laboratories stock.

Abbott Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Abbott Laboratories's total ESG risk score

Total ESG risk: 32.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 01/01/2019) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Abbott Laboratories's environmental score

Environmental score: 3.98/100

Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Abbott Laboratories's social score

Social score: 20.71/100

Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Abbott Laboratories's governance score

Governance score: 13.15/100

Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Abbott Laboratories's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Abbott Laboratories was last rated for ESG on: 2019-01-01.

Total ESG score 32.35
Total ESG percentile 60.66
Environmental score 3.98
Environmental score percentile 5
Social score 20.71
Social score percentile 5
Governance score 13.15
Governance score percentile 5
Level of controversy 3

Abbott Laboratories share dividends

42%

Dividend payout ratio: 41.92% of net profits

Recently Abbott Laboratories has paid out, on average, around 41.92% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.47% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.47% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $1.53 per share.

While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.

Abbott Laboratories's most recent dividend payout was on 17 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 14 April 2021 (the "ex-dividend date").

Have Abbott Laboratories's shares ever split?

Abbott Laboratories's shares were split on a 10000:4798 basis on 2 January 2013. So if you had owned 4798 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.

Abbott Laboratories share price volatility

Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as US$60.667 up to US$128.54. A popular way to gauge a stock's volatility is its "beta".

ABT.US volatility(beta: 0.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.7305. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).

Abbott Laboratories overview

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site